Competition Insurance Physicians Prescription 
World of DTC Marketing
MARCH 1, 2022
Hospitals, physicians, and clinical care made up more than half of the total healthcare spending in 2019. Most Americans don’t have much of a choice for their insurance plan. Mor than 54 % get health insurance through their employer. The lack of choice limits competition, which can drive prices higher.
Healthcare Success
JULY 5, 2022
Marketing to doctors, physicians, surgeons, and other health care professionals can be extremely challenging, complicated, and expensive. Not only are doctors and decision-makers difficult to reach—and even more difficult to persuade—you have to contend with a ton of competition. How to Market to Physicians and Doctors in Five Steps .
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PM360
SEPTEMBER 21, 2023
As many in the industry now know, the Inflation Reduction Act (IRA) is the most significant reform of Medicare prescription drug coverage since the creation of Part D and has wide-ranging implications for the healthcare industry. They do not have biosimilar or generic competition available in the market.
Clarivate
JULY 5, 2023
The Biosimilars Forum has hailed 2022 as a watershed year that could create a more competitive U.S. biologics market and reduce prescription drug costs. The larger discount will be available to insurers who choose not to utilize those discounts and rebates. from 91% in 2023 to 36% by 2031.
Clarivate
APRIL 18, 2024
RxPass offers more than 50 select prescriptions at no additional cost for $5 per month. Amazon also introduced Health Condition Programs, which partners with digital health companies such as Omada Health to connect members of health plans and employer-sponsored insurance with covered digital benefits.
Clarivate
OCTOBER 25, 2023
While more expensive than type 2 diabetes drugs, blood thinners follow a similar pattern of high prescription volumes. Insurers could respond by raising coinsurance rates, but the number of beneficiaries taking those drugs is relatively small. exclusions exist for orphan drug designation and biosimilar competition ). With 27.5%
PM360
APRIL 7, 2023
However, we expect drugs without strong therapeutic alternatives to have an advantage in negotiations, while drugs in highly competitive classes will be negotiating from a weaker position. Truth is, many patients already pay less than the newly announced costs, whether they are covered by traditional health insurance, Medicare, or Medicaid.
Expert insights. Personalized for you.
154 
Let's personalize your content